Skip to Content

Patrick Murta

Chief Technology Officer, BehaVR

Patrick is Chief Technology Officer at BehaVR, a leading virtual reality (VR) digital therapeutics company with a behavioral health focus. He leads the BehaVR platform and associated teams, which translate proven science into effective and engaging VR therapeutics for mental and behavioral health.

He aims to create VR tools that enable a resilient world, liberated from fear and pain. The healthcare-connected platform ensures patient centricity, provider workflow integration, and an effective and engaging model powered by the platform engine.

Patrick came to BehaVR from Humana, where he spent 23 years providing leading healthcare solutions. Most recently at Humana, he served as Chief Interoperability Architect and Fellow. In that role, he provided strategy, architecture, and product to achieve integrated care delivery. Patrick is a frequent speaker and provides thought leadership in the industry. He has served as co-chief architect of the Federal Office of the National Coordinator’s FHIR at Scale Task Force (FAST), a leader of the Da Vinci operating committee and architecture team, and others. He currently helps lead the Standards Forum for VR. He is a co-inventor on two patents related to healthcare business rules management and integration of clinical insights in EHR workflow. His mission is to use contemporary technical approaches to optimize experiences and help patients achieve optimal wellness.

Patrick's experience extends to the original HIPAA X12 implementations. He has designed and implemented enterprise EDI gateways, enterprise HIEs, utilization and case management platforms, business rules management systems for case and utilization management, predictive models for member health and safety, and bi-directional payer and EHR integration.

Over his career, Patrick has architected and implemented leading healthcare solutions, including a CIO 100 award winner in 2020. He recently co-authored an FHIR interoperability implementation guide, which HL7 approved for trial use in 2022.